Sugi Predict

Sugi Predict / Compounds / SCHEMBL4245177

SCHEMBL4245177

SCHEMBL4245177

N=C(N)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2nc[nH]c(=O)c12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.55
▸ HTT P42858 3/20 0.55
▸ RAB9A P51151 2/20 0.55
▸ MAPT P10636 2/20 0.55
▸ PAX8 Q06710 2/20 0.55
▸ NPC1 O15118 1/20 0.55
▸ GALR3 O60755 1/20 0.55
▸ S1PR4 O95977 1/20 0.55
▸ S1PR1 P21453 1/20 0.55
▸ ADK P55263 6/20 0.51
▸ TP53 P04637 4/20 0.48
▸ STAT6 P42226 2/20 0.48
▸ HIF1A Q16665 2/20 0.48
▸ DOT1L Q8TEK3 2/20 0.48
▸ GMNN O75496 1/20 0.47
▸ LMNA P02545 1/20 0.47
▸ NFKB1 P19838 1/20 0.47
▸ DNMT1 P26358 1/20 0.47
▸ THPO P40225 1/20 0.47
▸ MTOR P42345 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6743468 0.99 ALDH1A1 (0.54) ALDH1A1HTTRAB9AMAPTPAX8
SCHEMBL7213421 0.92 ALDH1A1 (0.57) ALDH1A1HTTRAB9AMAPTPAX8
SCHEMBL29386428 0.84 PNP (0.54) ALDH1A1HTTRAB9AMAPTPAX8
SCHEMBL4245171 0.83 ALDH1A1 (0.45) ALDH1A1HTTRAB9AMAPTPAX8
SCHEMBL23211481 0.83 ADK (0.54) ALDH1A1HTTRAB9AMAPTPAX8
SCHEMBL24166706 0.83 ADK (0.54) ALDH1A1HTTRAB9AMAPTPAX8
SCHEMBL23989399 0.83 ADK (0.54) ALDH1A1HTTRAB9AMAPTPAX8
SCHEMBL21137753 0.83 ADK (0.54) ALDH1A1HTTRAB9AMAPTPAX8
SCHEMBL22990432 0.83 ADK (0.54) ALDH1A1HTTRAB9AMAPTPAX8
SCHEMBL18510882 0.83 ADK (0.54) ALDH1A1HTTRAB9AMAPTPAX8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1813278-B9 Nucleoside analogs with carboxamidine modified monocyclic base VALEANT PHARMACEUTICALS NORTH AMERICA (US) 2015-04-01 — — EP disclosed
EP-1813278-B1 Nucleoside analogs with carboxamidine modified monocyclic base VALEANT PHARMACEUTICALS NORTH AMERICA (US) 2014-10-29 — — EP disclosed
US-7638496-B2 Viramidine (Ribamidine HCL) to treat infections, infestations, tumors and hypersensitivities to autoimmune diseases; viricide; prodrug; less toxic than Ribavirin; selective modulation of Type 1 and Type 2 responses relative to one another for a bimodal effect VALEANT PHARMACEUTICALS NORTH AMERICA (US) 2009-12-29 — — US disclosed
US-20090176721-A1 NUCLEOSIDE ANALOGS WITH CARBOXAMIDINE MODIFIED MONOCYCLIC BASE VALEANT PHARMACEUTICALS NORTH AMERICA (US) 2009-07-09 — — US disclosed
EP-1257281-B8 NUCLEOSIDE ANALOGS WITH CARBOXAMIDINE MODIFIED MONOCYCLIC BASE VALEANT PHARMACEUTICALS NORTH (US) 2008-01-23 — — EP disclosed
EP-1257281-B1 NUCLEOSIDE ANALOGS WITH CARBOXAMIDINE MODIFIED MONOCYCLIC BASE RIBAPHARM INC (US) 2007-11-07 — — EP disclosed
EP-1813278-A1 Nucleoside analogs with carboxamidine modified monocyclic base Ribapharm, Inc. (US) 2007-08-01 — — EP disclosed
US-20050159372-A1 Nucleoside analogs with carboxamidine modified monocyclic base VALEANT CANADA LP (CA) 2005-07-21 — — US disclosed
US-6831069-B2 Having substituents at the C4' and C5' positions of the ribofuranose moiety; anticancer and immunomodulating effects at reduced cytotoxicity; treating autoimmune diseases, cancer, dermatitis RIBAPHARM INC. 2004-12-14 — — US disclosed
EP-1363581-A2 PYRROLO(2,3-D)PYRIMIDINE NUCLEOSIDE ANALOGS Ribapharm, Inc. (US) 2003-11-26 — — EP disclosed
EP-1278528-A4 NUCLEOSIDE ANALOGS WITH CARBOXAMIDINE-MODIFIED BICYCLIC BASE TAM ROBERT (US) 2003-03-19 — — EP disclosed
EP-1257281-A4 NUCLEOSIDE ANALOGS WITH CARBOXAMIDINE MODIFIED MONOCYCLIC BASE ICN PHARMACEUTICALS (US) 2003-03-19 — — EP disclosed
EP-1278528-A1 NUCLEOSIDE ANALOGS WITH CARBOXAMIDINE-MODIFIED BICYCLIC BASE ICN Pharmaceuticals, Inc. (US) 2003-01-29 — — EP disclosed
WO-2002100354-A2 PYRROLO[2,3-D]PYRIMIDINE NUCLEOSIDE ANALOGS RIBAPHARM INC. (US) 2002-12-19 — — WO disclosed
EP-1257281-A1 NUCLEOSIDE ANALOGS WITH CARBOXAMIDINE MODIFIED MONOCYCLIC BASE ICN Pharmaceuticals, Inc. (US) 2002-11-20 — — EP disclosed
US-20020035077-A1 Pyrrolo[2,3-d]pyrimidine nucleoside analogs CEQUENT PHARMACEUTICALS, INC. 2002-03-21 — — US disclosed
WO-2001060381-A1 NUCLEOSIDE ANALOGS WITH CARBOXAMIDINE-MODIFIED BICYCLIC BASE RIBAPHARM CORP. (US) 2001-08-23 — — WO disclosed
WO-2001060379-A1 NUCLEOSIDE ANALOGS WITH CARBOXAMIDINE MODIFIED MONOCYCLIC BASE RIBAPHARM CORP. (US) 2001-08-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020035077-A1 Pyrrolo[2,3-d]pyrimidine nucleoside analogs TYMP, DPYD, TYMS ALDH1A1 2327/4885HTT 3587/4885RAB9A 3507/4885
US-20090176721-A1 NUCLEOSIDE ANALOGS WITH CARBOXAMIDINE MODIFIED MONOCYCLIC BASE NT5C2, PNP, SLC29A1 ALDH1A1 1998/4885HTT 4301/4885RAB9A 1709/4885
US-20050159372-A1 Nucleoside analogs with carboxamidine modified monocyclic base NT5C2, PNP, SLC29A1 ALDH1A1 1998/4885HTT 4301/4885RAB9A 1709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.